Sustainability & Climate

Despite citizenship law debates, investor demand for Portugal's Golden Visa remains strong, signaling a strategic shift towards long-term residency.

FDA greenlights a novel, AI-discovered therapy for a Phase 1 trial, offering new hope for children with devastating central nervous system tumors.

As co-founder Jürgen Bickel steps down, 14-year veteran David Männer takes the helm to navigate Storz & Bickel's future and drive Canopy's U.S. plans.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Biotech pioneer Stratum Biosciences lands $2M seed funding to scale its AI platform, mining 200,000 skin samples to unlock new frontiers in dermatology.

For decades, ill-fitting gear has endangered female first responders. Now, a new initiative aims to deliver safety, equity, and dignity through design.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

A major investment aims to develop biomarkers for TAND, the neuropsychiatric challenges affecting most with TSC, offering new hope for families.

Amid a major leadership change, Sonorous Neurovascular pushes its pioneering BosSTENT™ for pulsatile tinnitus sufferers closer to market approval.

After a massive breach exposed sensitive genetic data, 23andMe's Canadian settlement is final. Learn what went wrong and how to claim your share.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.

Launched in 2025, Mellow hit $110M in sales in nine months by mastering TikTok. Now it aims to own the $300B sleep market, but can the product live up to the hype?

A new report shows 6 in 10 Brits now prefer revisiting holiday spots. Discover the rise of the 'Return Economy' and how it's reshaping travel.

A French biopharma's leap in synthetic lipid production de-risks its lead drug, eyes a vast sepsis market, and creates new commercial avenues.

From a $20k loan to a major wellness player, a women-founded brand proves sustainability and science are the future of sleep and business.

Crinetics Pharmaceuticals aims to disrupt Brazil's acromegaly treatment with Palsonify, a once-daily pill challenging the standard of monthly injections.

As outdoor recreation booms and volunteer support wanes, a tech and auto partnership is scaling up efforts to restore threatened public land trails.

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.